CSIMarket



Worst Performing Stocks In Healthcare Sector Today



 1 Day   Week  Current Month of June  30 Days 
Current Quarter Q2 of 2024  90 Days    Ytd    12 Months 
 

Shares fell by -0.34% on average, in Healthcare Sector today.

Here are the Worst performing stocks in Healthcare Sector.




DMTK

$0.1455

$-0.1870 -56.24%
Today's


DMTK

$0.1455

$-0.1870 -56.24%



Dermtech Inc

Dermtech Inc shares declined -56.24% today.


Dermtech Inc is a biotechnology company that specializes in non-invasive diagnostic tests for skin cancer and other skin conditions. Their business model revolves around developing and commercializing their proprietary technology, which allows for the accurate and early detection of skin cancer through a simple adhesive patch. By providing dermatologists with a less invasive and more efficient diagnostic tool, Dermtech aims to improve patient outcomes and revolutionize the field of dermatology.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 5.050 mill. $ 13.370 mill. $ -101.807 mill. 35 mill. - Y/Y 24.01 %
Market Cap. Revenues TTM Net Income TTM

$ 5.050 mill.


$ 13.370 mill.


$ -101.807 mill.

Employees Shares Outstanding P/E

-


35 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 24.01 %


MRQ Y/Y - %



ZNTL

$4.14

$-4.2500 -50.66%
Today's


ZNTL

$4.14

$-4.2500 -50.66%



Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc stock went down -50.66% today.


Zentalis Pharmaceuticals Inc is a biopharmaceutical company that focuses on the discovery and development of small molecule therapies for the treatment of various types of cancer. Their business model revolves around leveraging their expertise in drug discovery, conducting clinical trials, and ultimately commercializing effective cancer treatments. By leveraging their innovative research and development capabilities, Zentalis aims to address unmet medical needs and improve the lives of cancer patients worldwide.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 294.735 mill. $ 40.560 mill. $ -219.003 mill. 71 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 294.735 mill.


$ 40.560 mill.


$ -219.003 mill.

Employees Shares Outstanding P/E

105


71 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



CALA

$0.0125

$-0.0075 -37.50%
Today's


CALA

$0.0125

$-0.0075 -37.50%



Calithera Biosciences Inc

Calithera Biosciences Inc stock went down -37.50% today.


Calithera Biosciences Inc is a biotechnology company that specializes in developing novel small molecule drugs to treat and potentially cure cancer. Their business model focuses on leveraging their expertise in tumor metabolism to discover and develop innovative therapies that target specific enzymes and pathways involved in cancer cell growth and survival.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.071 mill. $ - mill. $ -21.290 mill. 6 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.071 mill.


$ - mill.


$ -21.290 mill.

Employees Shares Outstanding P/E

-


6 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ATAO

$0.0301

$-0.0164 -35.27%
Today's


ATAO

$0.0301

$-0.0164 -35.27%



Altair International Corp

Altair International Corp stock dropped -35.27% today.


Altair International Corp is a diversified company with a business model focused on providing a range of products and services. Their offerings span various sectors, including technology, finance, health, and real estate. By leveraging their expertise and network, Altair International Corp aims to capitalize on opportunities and generate revenue through strategic investments, partnerships, and market expansion.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.750 mill. $ - mill. $ -1.211 mill. 25 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.750 mill.


$ - mill.


$ -1.211 mill.

Employees Shares Outstanding P/E

-


25 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



AZTR

$0.1554

$-0.0783 -33.50%
Today's


AZTR

$0.1554

$-0.0783 -33.50%



Azitra Inc

Azitra Inc stock dropped -33.50% today.


Azitra Inc is a company that operates on a business model focused on developing and commercializing microbiome-based therapeutics for various skin conditions. It aims to use the potential of the human skin microbiome to develop innovative and effective treatments.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3.136 mill. $ - mill. $ -14.217 mill. 20 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 3.136 mill.


$ - mill.


$ -14.217 mill.

Employees Shares Outstanding P/E

-


20 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



LPCN

$7.18

$-3.5100 -32.83%
Today's


LPCN

$7.18

$-3.5100 -32.83%



Lipocine Inc

Lipocine Inc stock went down -32.83% today.


Lipocine Inc is a pharmaceutical company focused on developing oral drug delivery systems for hormone therapeutics. Their business model involves conducting research and development to create innovative products that address unmet medical needs in areas such as testosterone replacement therapy and hypogonadism. The company aims to commercialize these proprietary drug candidates and collaborate with industry partners to enhance their potential reach and impact.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 37.586 mill. $ -2.851 mill. $ -16.352 mill. 5 mill. - Y/Y 164.58 %
Market Cap. Revenues TTM Net Income TTM

$ 37.586 mill.


$ -2.851 mill.


$ -16.352 mill.

Employees Shares Outstanding P/E

-


5 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 164.58 %


MRQ Y/Y - %



CLRD

$0.35

$-0.1500 -30.00%
Today's


CLRD

$0.35

$-0.1500 -30.00%



Clearday Inc

Clearday Inc stock went down -30.00% today.


ClearDay Inc*s business model focuses on providing high-quality and innovative products or services to meet the needs of its customers, while aiming to generate revenue and achieve profitability through strategic partnerships and effective marketing strategies.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 9.134 mill. $ 7.543 mill. $ -16.712 mill. 26 mill. - Y/Y -72.79 %
Market Cap. Revenues TTM Net Income TTM

$ 9.134 mill.


$ 7.543 mill.


$ -16.712 mill.

Employees Shares Outstanding P/E

-


26 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -72.79 %


MRQ Y/Y - %



TSHA

$2.97

$-1.0600 -26.30%
Today's


TSHA

$2.97

$-1.0600 -26.30%



Taysha Gene Therapies Inc

Taysha Gene Therapies Inc shares went down -26.30% today.


Taysha Gene Therapies Inc operates under a business model focused on developing and commercializing innovative genetic therapies to treat and potentially cure patients with rare monogenic diseases. Utilizing cutting-edge technologies, the company aims to bring transformative treatments to market in order to improve the lives of individuals suffering from these rare genetic disorders.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 373.331 mill. $ 14.349 mill. $ -215.030 mill. 126 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 373.331 mill.


$ 14.349 mill.


$ -215.030 mill.

Employees Shares Outstanding P/E

-


126 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



VRPX

$0.5701

$-0.1890 -24.90%
Today's


VRPX

$0.5701

$-0.1890 -24.90%



Virpax Pharmaceuticals Inc

Virpax Pharmaceuticals Inc shares declined -24.90% today.


Virpax Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing innovative non-opioid products to address the unmet needs in pain management. Their business model revolves around research, development, and commercialization of these non-opioid solutions to provide effective and safe pain relief options for patients.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.668 mill. $ - mill. $ -13.615 mill. 1 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.668 mill.


$ - mill.


$ -13.615 mill.

Employees Shares Outstanding P/E

-


1 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



NGNE

$30.32

$-9.6800 -24.20%
Today's


NGNE

$30.32

$-9.6800 -24.20%



Neurogene Inc

Neurogene Inc stock declined -24.20% today.





Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 512.521 mill. $ - mill. $ -23.532 mill. 17 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 512.521 mill.


$ - mill.


$ -23.532 mill.

Employees Shares Outstanding P/E

-


17 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



SCNI

$4.33

$-1.2700 -22.68%
Today's


SCNI

$4.33

$-1.2700 -22.68%



Scinai Immunotherapeutics Ltd

Scinai Immunotherapeutics Ltd stock went down -22.68% today.





Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 676.618 mill. $ - mill. $ 6.500 mill. 156 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 676.618 mill.


$ - mill.


$ 6.500 mill.

Employees Shares Outstanding P/E

-


156 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y 0.00 %



TLPH

$0.7811

$-0.2119 -21.34%
Today's


TLPH

$0.7811

$-0.2119 -21.34%



Talphera Inc

Talphera Inc stock dropped -21.34% today.





Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 19.310 mill. $ - mill. $ -9.682 mill. 25 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 19.310 mill.


$ - mill.


$ -9.682 mill.

Employees Shares Outstanding P/E

-


25 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



CYCN

$2.21

$-0.5779 -20.73%
Today's


CYCN

$2.21

$-0.5779 -20.73%



Cyclerion Therapeutics Inc

Cyclerion Therapeutics Inc stock dropped -20.73% today.


Cyclerion Therapeutics Inc*s business model focuses on developing and commercializing innovative therapies for serious and chronic diseases by targeting soluble guanylate cyclase (sGC).


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 6.157 mill. $ - mill. $ -17.100 mill. 3 mill. 1.03 Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 6.157 mill.


$ - mill.


$ -17.100 mill.

Employees Shares Outstanding P/E

-


3 mill.


1.03

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



SABS

$2.58

$-0.6700 -20.62%
Today's


SABS

$2.58

$-0.6700 -20.62%



Sab Biotherapeutics Inc

Sab Biotherapeutics Inc stock dropped -20.62% today.


Sab Biotherapeutics Inc*s business model focuses on developing and producing innovative antibody therapeutics using advanced genetic engineering techniques.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 13.521 mill. $ 4.095 mill. $ -27.212 mill. 5 mill. - Y/Y -64.69 %
Market Cap. Revenues TTM Net Income TTM

$ 13.521 mill.


$ 4.095 mill.


$ -27.212 mill.

Employees Shares Outstanding P/E

-


5 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -64.69 %


MRQ Y/Y - %



LADX

$2.13

$-0.4900 -18.70%
Today's


LADX

$2.13

$-0.4900 -18.70%



Ladrx Corporation

Ladrx Corporation stock dropped -18.70% today.


Ladrx Corporation operates as a global technology solutions provider, offering a range of products and services in various industries. Their business model revolves around leveraging innovative technologies to develop tailored solutions for their clients, with a focus on enhancing operational efficiency and driving digital transformation. By combining their expertise in multiple domains and maintaining strong partnerships, Ladrx aims to deliver value-driven solutions to meet the evolving needs of businesses worldwide.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1.055 mill. $ - mill. $ 1.662 mill. 1 mill. 0.62 Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 1.055 mill.


$ - mill.


$ 1.662 mill.

Employees Shares Outstanding P/E

-


1 mill.


0.62

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



BSGM

$0.33

$-0.0740 -18.32%
Today's


BSGM

$0.33

$-0.0740 -18.32%



Biosig Technologies Inc

Biosig Technologies Inc stock dropped -18.32% today.


Biosig Technologies Inc is a medical device company that specializes in innovative solutions for the healthcare industry. Their business model revolves around developing and commercializing proprietary technologies, particularly in the field of physiological signal monitoring. By creating and marketing advanced medical devices, Biosig aims to improve patient outcomes and provide healthcare professionals with valuable tools for better diagnostics and treatment.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3.253 mill. $ -272.981 mill. $ -4.843 mill. 10 mill. 0.18 Y/Y -89.63 %
Market Cap. Revenues TTM Net Income TTM

$ 3.253 mill.


$ -272.981 mill.


$ -4.843 mill.

Employees Shares Outstanding P/E

-


10 mill.


0.18

Revenue Growth Income Growth

MRQ Y/Y -89.63 %


MRQ Y/Y - %



SQZB

$0.037

$-0.0080 -17.78%
Today's


SQZB

$0.037

$-0.0080 -17.78%



Sqz Biotechnologies Company

Sqz Biotechnologies Company shares went down -17.78% today.


Sqz Biotechnologies Company*s business model revolves around developing and commercializing innovative cell engineering platforms for multiple applications across the healthcare industry.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1.091 mill. $ - mill. $ 0.000 mill. 29 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 1.091 mill.


$ - mill.


$ 0.000 mill.

Employees Shares Outstanding P/E

-


29 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



BFRG

$1.98

$-0.4100 -17.15%
Today's


BFRG

$1.98

$-0.4100 -17.15%



Bullfrog Ai Holdings Inc

Bullfrog Ai Holdings Inc stock declined -17.15% today.


Bullfrog Ai Holdings Inc utilizes artificial intelligence technology to develop and provide advanced solutions for businesses. Their business model focuses on offering AI-powered products and services to help companies optimize their operations and decision-making processes.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 14.629 mill. $ - mill. $ -5.934 mill. 7 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 14.629 mill.


$ - mill.


$ -5.934 mill.

Employees Shares Outstanding P/E

-


7 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



AMIX

$1.12

$-0.2300 -17.04%
Today's


AMIX

$1.12

$-0.2300 -17.04%



Autonomix Medical Inc

Autonomix Medical Inc shares declined -17.04% today.





Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 16.454 mill. $ - mill. $ -16.906 mill. 15 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 16.454 mill.


$ - mill.


$ -16.906 mill.

Employees Shares Outstanding P/E

-


15 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



EMED

$0.0005

$-0.0001 -16.67%
Today's


EMED

$0.0005

$-0.0001 -16.67%



Electromedical Technologies inc

Electromedical Technologies Inc stock declined -16.67% today.


Electromedical Technologies Inc*s business model revolves around the development and commercialization of innovative medical devices. The company focuses on creating and selling safe, non-invasive therapeutic devices that utilize bioelectric technology to address various medical conditions. Through its comprehensive research, development, and marketing strategies, Electromedical Technologies Inc aims to provide effective solutions while adhering to regulatory standards in the healthcare industry.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.232 mill. $ 1.360 mill. $ -2.503 mill. 465 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.232 mill.


$ 1.360 mill.


$ -2.503 mill.

Employees Shares Outstanding P/E

-


465 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



GRST

$0.0005

$-0.0001 -16.67%
Today's


GRST

$0.0005

$-0.0001 -16.67%



Ethema Health Corporation

Ethema Health Corporation shares declined -16.67% today.


Ethema Health Corporation operates as a healthcare management company that provides specialized services for the treatment of addiction and mental health disorders. Their business model focuses on offering comprehensive care through a network of treatment centers, with a combination of inpatient and outpatient programs, therapy sessions, and support services. The company aims to generate revenue by leveraging insurance reimbursements, self-pay options, and partnerships with government agencies and healthcare organizations.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1.865 mill. $ 5.345 mill. $ 1.154 mill. 3,729 mill. - Y/Y 0.00 %
Market Cap. Revenues TTM Net Income TTM

$ 1.865 mill.


$ 5.345 mill.


$ 1.154 mill.

Employees Shares Outstanding P/E

-


3,729 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 0.00 %


MRQ Y/Y - %



CNSP

$2.42

$-0.4800 -16.55%
Today's


CNSP

$2.42

$-0.4800 -16.55%



Cns Pharmaceuticals Inc

Cns Pharmaceuticals Inc shares dropped -16.55% today.


CNS Pharmaceuticals Inc*s business model focuses on developing innovative solutions and treatments for central nervous system diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 21.085 mill. $ 0.034 mill. $ -17.464 mill. 9 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 21.085 mill.


$ 0.034 mill.


$ -17.464 mill.

Employees Shares Outstanding P/E

-


9 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



HLVX

$12.8

$-2.4900 -16.29%
Today's


HLVX

$12.8

$-2.4900 -16.29%



Hillevax Inc

Hillevax Inc stock dropped -16.29% today.


Hillevax Inc*s business model is centered around a specific product or service that they offer to customers.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 499.706 mill. $ - mill. $ -107.794 mill. 39 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 499.706 mill.


$ - mill.


$ -107.794 mill.

Employees Shares Outstanding P/E

-


39 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



SLS

$1.06

$-0.1900 -15.20%
Today's


SLS

$1.06

$-0.1900 -15.20%



Sellas Life Sciences Group Inc

Sellas Life Sciences Group Inc stock went down -15.20% today.


Sellas Life Sciences Group Inc is a biopharmaceutical company that focuses on developing and commercializing immunotherapeutic products for various cancer indications, utilizing innovative technologies. The company aims to meet the need for more effective treatment options by leveraging its expertise in immuno-oncology and precision medicine.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 47.502 mill. $ - mill. $ -35.809 mill. 45 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 47.502 mill.


$ - mill.


$ -35.809 mill.

Employees Shares Outstanding P/E

-


45 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



CANF

$2.73

$-0.4800 -14.95%
Today's


CANF

$2.73

$-0.4800 -14.95%



Can fite Biopharma Ltd

Can Fite Biopharma Ltd stock dropped -14.95% today.


Can-Fite Biopharma Ltd is a pharmaceutical company that focuses on developing and commercializing drugs for the treatment of inflammatory diseases and cancer.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 2,226.987 mill. $ 0.810 mill. $ -10.173 mill. 816 mill. - Y/Y -5.04 %
Market Cap. Revenues TTM Net Income TTM

$ 2,226.987 mill.


$ 0.810 mill.


$ -10.173 mill.

Employees Shares Outstanding P/E

-


816 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -5.04 %


MRQ Y/Y - %



CING

$0.57

$-0.1000 -14.93%
Today's


CING

$0.57

$-0.1000 -14.93%



Cingulate Inc

Cingulate Inc shares went down -14.93% today.


Cingulate Inc operates as a software development company, specializing in delivering innovative solutions for various industries. With a focus on cutting-edge technologies, they provide customized software products and services to meet the specific needs of their clients. Their business model revolves around developing and implementing software solutions that optimize processes and enhance efficiency within organizations.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.516 mill. $ - mill. $ -23.535 mill. 1 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.516 mill.


$ - mill.


$ -23.535 mill.

Employees Shares Outstanding P/E

-


1 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



SCLX

$1.83

$-0.3200 -14.88%
Today's


SCLX

$1.83

$-0.3200 -14.88%



Scilex Holding Company

Scilex Holding Company shares went down -14.88% today.


Scilex Holding Company operates as a pharmaceutical company focused on the development and commercialization of prescription drugs. Through its business model, it aims to identify and acquire assets that have the potential to address unmet medical needs and improve patient outcomes. The company primarily focuses on developing innovative, differentiated products in the therapeutic areas of pain management and neurology.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 255.849 mill. $ 71.315 mill. $ -116.919 mill. 140 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 255.849 mill.


$ 71.315 mill.


$ -116.919 mill.

Employees Shares Outstanding P/E

-


140 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



AVTE

$1.41

$-0.2400 -14.55%
Today's


AVTE

$1.41

$-0.2400 -14.55%



Aerovate Therapeutics Inc

Aerovate Therapeutics Inc shares dropped -14.55% today.


Aerovate Therapeutics Inc*s business model is focused on developing and commercializing innovative therapeutic solutions for respiratory diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 38.973 mill. $ - mill. $ -72.097 mill. 28 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 38.973 mill.


$ - mill.


$ -72.097 mill.

Employees Shares Outstanding P/E

10


28 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



SLRX

$2.9882

$-0.4918 -14.13%
Today's


SLRX

$2.9882

$-0.4918 -14.13%



Salarius Pharmaceuticals inc

Salarius Pharmaceuticals Inc stock went down -14.13% today.


Salarius Pharmaceuticals Inc*s business model revolves around the development and commercialization of innovative treatments for rare and aggressive cancers.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 12.534 mill. $ - mill. $ -8.917 mill. 4 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 12.534 mill.


$ - mill.


$ -8.917 mill.

Employees Shares Outstanding P/E

-


4 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



NNVC

$1.64

$-0.2600 -13.68%
Today's


NNVC

$1.64

$-0.2600 -13.68%



Nanoviricides inc

Nanoviricides Inc stock declined -13.68% today.


Nanoviricides Inc. is a pharmaceutical company that operates on a business model based on the development and commercialization of nanomedicines.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 19.319 mill. $ - mill. $ -9.508 mill. 12 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 19.319 mill.


$ - mill.


$ -9.508 mill.

Employees Shares Outstanding P/E

-


12 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



AEON

$1.34

$-0.2100 -13.55%
Today's


AEON

$1.34

$-0.2100 -13.55%



Aeon Biopharma inc

Aeon Biopharma Inc shares went down -13.55% today.


Aeon Biopharma Inc.*s business model focuses on the development and commercialization of biopharmaceutical products, emphasizing innovation and collaboration for the advancement of healthcare.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 82.238 mill. $ - mill. $ 4.825 mill. 61 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 82.238 mill.


$ - mill.


$ 4.825 mill.

Employees Shares Outstanding P/E

-


61 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y 451.84 %



TCRT

$0.8301

$-0.1299 -13.53%
Today's


TCRT

$0.8301

$-0.1299 -13.53%



Alaunos Therapeutics Inc

Alaunos Therapeutics Inc shares dropped -13.53% today.


Alaunos Therapeutics Inc is a biotechnology company that operates on a research and development business model. Their focus is on discovering and developing innovative therapies for various diseases and medical conditions. Through their scientific expertise and collaborations, they aim to bring novel treatments to market to improve patient outcomes.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 199.262 mill. $ - mill. $ -36.456 mill. 240 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 199.262 mill.


$ - mill.


$ -36.456 mill.

Employees Shares Outstanding P/E

-


240 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



FNCH

$1.28

$-0.2000 -13.51%
Today's


FNCH

$1.28

$-0.2000 -13.51%



Finch Therapeutics Group Inc

Finch Therapeutics Group Inc shares went down -13.51% today.


Finch Therapeutics Group Inc*s business model revolves around developing microbiome-based therapies for various diseases and conditions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 2.054 mill. $ - mill. $ -100.313 mill. 2 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 2.054 mill.


$ - mill.


$ -100.313 mill.

Employees Shares Outstanding P/E

-


2 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



XBIT

$5.26

$-0.8200 -13.49%
Today's


XBIT

$5.26

$-0.8200 -13.49%



Xbiotech Inc

Xbiotech Inc stock declined -13.49% today.


Xbiotech Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic antibodies. They seek to address unmet medical needs by leveraging their proprietary True Human antibody technology.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 160.135 mill. $ - mill. $ -30.743 mill. 30 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 160.135 mill.


$ - mill.


$ -30.743 mill.

Employees Shares Outstanding P/E

-


30 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ASLN

$0.3121

$-0.0480 -13.33%
Today's


ASLN

$0.3121

$-0.0480 -13.33%



Aslan Pharmaceuticals Limited

Aslan Pharmaceuticals Limited shares went down -13.33% today.


Aslan Pharmaceuticals Limited is a biotechnology company with a focus on developing novel therapeutics for cancer. They aim to leverage their expertise in drug discovery and development to develop innovative treatments that target specific pathways involved in tumor growth. Aslan Pharmaceuticals adopts a collaborative approach, partnering with global pharmaceutical and biotech companies to advance their drug candidates through clinical trials and ultimately bring them to market.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 106.910 mill. $ - mill. $ -51.382 mill. 343 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 106.910 mill.


$ - mill.


$ -51.382 mill.

Employees Shares Outstanding P/E

-


343 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



BIOL

$0.129

$-0.0196 -13.19%
Today's


BIOL

$0.129

$-0.0196 -13.19%



Biolase Inc

Biolase Inc shares declined -13.19% today.


Biolase Inc*s business model revolves around developing and manufacturing dental laser systems and related products.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.152 mill. $ 49.382 mill. $ -25.166 mill. 1 mill. - Y/Y -10.52 %
Market Cap. Revenues TTM Net Income TTM

$ 0.152 mill.


$ 49.382 mill.


$ -25.166 mill.

Employees Shares Outstanding P/E

-


1 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -10.52 %


MRQ Y/Y - %



TSOI

$0.0007

$-0.0001 -12.50%
Today's


TSOI

$0.0007

$-0.0001 -12.50%



Therapeutic Solutions International Inc

Therapeutic Solutions International Inc stock declined -12.50% today.


Therapeutic Solutions International Inc is a company that operates under a business model focused on researching, developing, and commercializing cutting-edge treatments and therapies for various medical conditions. Their approach involves identifying innovative technologies and products, conducting rigorous scientific research, and partnering with healthcare professionals and organizations to bring their solutions to the market. Through their business model, they aim to improve patient outcomes and revolutionize medical treatments across different fields.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 2.218 mill. $ - mill. $ -3.742 mill. 3,169 mill. 1.37 Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 2.218 mill.


$ - mill.


$ -3.742 mill.

Employees Shares Outstanding P/E

-


3,169 mill.


1.37

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



SKYE

$9.51

$-1.3500 -12.43%
Today's


SKYE

$9.51

$-1.3500 -12.43%



Skye Bioscience Inc

Skye Bioscience Inc shares went down -12.43% today.


Skye Bioscience Inc operates under a business model focused on developing and commercializing innovative therapeutic treatments. The company primarily engages in research and development activities to discover novel drugs targeting specific medical conditions and diseases. Skye Bioscience Inc aims to generate revenue by successfully bringing these drugs to market through partnerships, licensing agreements, or direct sales.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 266.279 mill. $ - mill. $ -38.244 mill. 28 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 266.279 mill.


$ - mill.


$ -38.244 mill.

Employees Shares Outstanding P/E

-


28 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ENZN

$0.15

$-0.0200 -11.76%
Today's


ENZN

$0.15

$-0.0200 -11.76%



Enzon Pharmaceuticals inc

Enzon Pharmaceuticals Inc stock dropped -11.76% today.


Enzon Pharmaceuticals Inc. operates under a business model that focuses on the research, development, and commercialization of therapeutic drugs to address unmet medical needs. The company primarily employs a licensing strategy, partnering with other pharmaceutical companies to advance their drug candidates through clinical development and regulatory approval. By leveraging collaborations and out-licensing opportunities, Enzon aims to bring new therapies to market efficiently while maximizing shareholder value.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 11.132 mill. $ 2.461 mill. $ 1.496 mill. 74 mill. 22,478.15 Y/Y 44.74 %
Market Cap. Revenues TTM Net Income TTM

$ 11.132 mill.


$ 2.461 mill.


$ 1.496 mill.

Employees Shares Outstanding P/E

-


74 mill.


22,478.15

Revenue Growth Income Growth

MRQ Y/Y 44.74 %


MRQ Y/Y 62.44 %



TRAW

$0.4601

$-0.0610 -11.71%
Today's


TRAW

$0.4601

$-0.0610 -11.71%



Traws Pharma inc

Traws Pharma Inc stock dropped -11.71% today.





Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 9.682 mill. $ 0.226 mill. $ -19.747 mill. 21 mill. - Y/Y 19.15 %
Market Cap. Revenues TTM Net Income TTM

$ 9.682 mill.


$ 0.226 mill.


$ -19.747 mill.

Employees Shares Outstanding P/E

-


21 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 19.15 %


MRQ Y/Y - %




 1 Day   Week  Current Month of June  30 Days 
Current Quarter Q2 of 2024  90 Days    Ytd    12 Months 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com